Frisco-based pharmacy services provider Soleo Health has been selected by Eisai Inc. as the sole specialty pharmacy distribution partner for Leqembi (lecanemab-irmb), a newly approved treatment for Alzheimer’s Disease.
Leqembi is an an anti-amyloid monoclonal antibody developed by Eisai and Biogen. On January 6, the companies announced that they’d been granted FDA approval under the accelerated approval pathway for the treatment of Alzheimer’s disease in patients with early AD.
The drug is used to treat mild cognitive impairment due to Alzheimer’s disease and “mild” Alzheimer’s disease (collectively known as early AD).
Patients receiving Leqembi will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center, Soleo said. The center’s staff includes physician specialists, nurse practitioners, therapy-care pharmacists, registered nurses, reimbursement specialists, and patient care ambassadors. The center is supported through Soleo’s specialty pharmacy locations nationwide, with pharmacy licensure in all 50 states.
Distributing through provider offices and Soleo’s own ambulatory infusion centers
Soleo Health will distribute Leqembi to provider offices and infusion centers, and will also administer it across its many Ambulatory Infusions Centers nationwide, including those owned and operated by Virtis Health, a provider division of Soleo Health.
“The selection of Soleo Health as the sole specialty pharmacy distributor for Leqembi reflects confidence in our clinical expertise and differentiated patient care model supporting patients in the neurology space,” Soleo CEO Drew Walk said in a statement. “Our partnership with Eisai will afford the Alzheimer’s community continued hope while we assist patients and their caregivers as they navigate their healthcare journey.”
His company says the combined service offering of Soleo Health and Virtis Health will provide patients “with flexible site of care options to meet their individual therapy needs and service expectations in a cost-effective setting.”
Soleo Health received ACHC accreditation in January 2021
In January 2022, Soleo Health joined only five other U.S. companies as an Accreditation Commission for Health Care (ACHC)-accredited specialty pharmacy with distinction in rare disease and orphan drugs. The company debuted on the Inc. 5000 list in 2020, marking substantial growth since its founding in 2014.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
The funding from the National Institutes of Health will help UNT HSC at Fort Worth advance its ongoing research on how Alzheimer's disease affects different racial and ethnic groups. Sid O'Bryant, executive director of UNT HSC's Institute for Translational Research, said there's never been a large-scale study like this before. “This award and project are nothing short of a bio behavioral ‘moonshot’ program," adds Brian Gladue, HSC executive VP for research and innovation.
-
The inaugural Techstars Physical Health Fort Worth Accelerator is kicking off with 10 startups who come from all over the map—from Dallas to cities across the U.S. as well as Canada, Switzerland, and Germany. They'll be taking up residence in Fort Worth for an "intensive" 13-week mentorship program that makes each eligible for $120,000 in seed funding from the UNT Health Science Center and Goff Capital. “We believe that Fort Worth can become the physical health innovation capital of the world, and this is an incredible next step to making that vision a reality,” says Dr. Sylvia Trent-Adams, president of…
-
Add public health advocacy to your to-do list. Here are three ways you can be an advocate for yourself and your community this year.
-
Called Radian, the solution is powered by Lightbeam’s health equity AI engine and requires only a ZIP code to aggregate clinical and social data across more than 4,500 factors. It gives providers an executive-level view of health disparities within a community.
-
Dunnu Devulapally has faced his own struggles with identity issues as a first-generation American as well as with substance abuse. Now he aims to help people facing these and other mental health-related issues by launching NRVE, a Dallas-based research nonprofit. Targeting younger generations, NRVE will focus on awareness in youth, support for veterans, support for homeless people, and research for substance abuse, domestic violence, and suicide prevention. With the information it collects, NRVE plans to become the “Google” for the mental health space, Devulapally told Dallas Innovates.
